NGGT 001
Alternative Names: NGGT-001Latest Information Update: 06 Jun 2024
At a glance
- Originator Xiamen University
- Developer Suzhou Nuojiebei Biotechnology; Xiamen University
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Cytochrome P-450 Family 4 replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bietti crystalline dystrophy
Most Recent Events
- 08 Feb 2023 Phase-I clinical trials in Bietti crystalline dystrophy in China (Subretinal) (NCT06302608)